Stockpolly
Search
CMPX · NASDAQ · Biotechnology

Compass Therapeutics (CMPX)

Develops oncology antibody candidates for tumor microenvironment biology.

$2.43
Pre-market−0.00 (−0.06%)
At close$2.44(+5.41%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000100000000
Cost of revenue000000000000
Gross profit000100000000
121513161217182116182027
Research & development9121011913131613141320
333544553477
Selling & marketing000000000000
General & administrative333544553477
Other expenses000000000000
Operating income−12−15−13−15−12−17−18−21−16−18−20−27
222222112222
Interest income222222112222
Other non-operating income0−2−2−2−2−2−1−1−2−2−2−2
Income before tax−10−13−11−13−10−15−17−20−14−16−18−25
Net income from continuing operations−10−13−11−13−10−15−17−20−14−16−18−25
Net income−10−13−11−13−10−15−17−20−14−16−18−25
EPS, basic−$0.08−$0.11−$0.08−$0.10−$0.08−$0.11−$0.12−$0.14−$0.10−$0.09−$0.10−$0.13
EPS, diluted−$0.08−$0.11−$0.08−$0.10−$0.08−$0.11−$0.12−$0.14−$0.10−$0.09−$0.10−$0.13
Weighted average shares, basic127128137138138137138138138185186187
Weighted average shares, diluted127128137138138137138138138185186187
EBITDA−11−13−10−13−10−15−16−20−14−15−18−25
Depreciation & amortization000000000000
EBIT−12−13−11−13−10−15−17−20−14−16−18−25